Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of developments in the global biopharmaceutical industry.

Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major developments in the business week ended 4 September 2020.

In the spotlight this week are new trial results in the SGLT2 inhibitor and cardiovascular spaces, antibodies in development for COVID-19, and how the pandemic is affecting consumers' perceptions of healthcare.

Stories mentioned in this episode:

(Also see "DAPA-CKD Data Put AstraZeneca’s Farxiga Out Front" - Scrip, 31 Aug, 2020.)

(Also see "Heart Failure A Key Future Market For Jardiance?" - Scrip, 2 Sep, 2020.)

(Also see "As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran" - Scrip, 1 Sep, 2020.)

(Also see "Regeneron and Roche Await Data On Potential COVID-19 Blockbuster" - Scrip, 3 Sep, 2020.)

(Also see "Post-COVID-19 Consumer Preferences A Guide For Pharma Strategy" - Scrip, 31 Aug, 2020.) 

 

Related Content

Topics

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel